Carbazeran citrateAldehyde oxidase substrate; PDE inhibitor CAS# 153473-94-0 |
- Baicalein
Catalog No.:BCN5599
CAS No.:491-67-8
- Luteolin
Catalog No.:BCN5600
CAS No.:491-70-3
- Chloroquine diphosphate
Catalog No.:BCC3915
CAS No.:50-63-5
- Apigenin
Catalog No.:BCN5658
CAS No.:520-36-5
- Vitamin D3
Catalog No.:BCN2186
CAS No.:67-97-0
- D-64131
Catalog No.:BCC1510
CAS No.:74588-78-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 153473-94-0 | SDF | Download SDF |
PubChem ID | 90488940 | Appearance | Powder |
Formula | C24H32N4O11 | M.Wt | 552.53 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 50 mM in water and to 100 mM in DMSO | ||
Chemical Name | [1-(6,7-dimethoxyphthalazin-1-yl)piperidin-4-yl] N-ethylcarbamate;2-hydroxypropane-1,2,3-tricarboxylic acid | ||
SMILES | CCNC(=O)OC1CCN(CC1)C2=NN=CC3=CC(=C(C=C32)OC)OC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O | ||
Standard InChIKey | QKMRPDVEKBYWPF-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H24N4O4.C6H8O7/c1-4-19-18(23)26-13-5-7-22(8-6-13)17-14-10-16(25-3)15(24-2)9-12(14)11-20-21-17;7-3(8)1-6(13,5(11)12)2-4(9)10/h9-11,13H,4-8H2,1-3H3,(H,19,23);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Aldehyde oxidase (AO) substrate. Exhibits activities as a phosphodiesterase inhibitor; produces concentration-dependent positive inotropic responses in isolated right atria. |
Carbazeran citrate Dilution Calculator
Carbazeran citrate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.8099 mL | 9.0493 mL | 18.0986 mL | 36.1971 mL | 45.2464 mL |
5 mM | 0.362 mL | 1.8099 mL | 3.6197 mL | 7.2394 mL | 9.0493 mL |
10 mM | 0.181 mL | 0.9049 mL | 1.8099 mL | 3.6197 mL | 4.5246 mL |
50 mM | 0.0362 mL | 0.181 mL | 0.362 mL | 0.7239 mL | 0.9049 mL |
100 mM | 0.0181 mL | 0.0905 mL | 0.181 mL | 0.362 mL | 0.4525 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Desmethoxy yangonin
Catalog No.:BCN2295
CAS No.:15345-89-8
- Fexofenadine HCl
Catalog No.:BCC4542
CAS No.:153439-40-8
- WHI-P180 hydrochloride
Catalog No.:BCC4243
CAS No.:153437-55-9
- PD153035 hydrochloride
Catalog No.:BCC3617
CAS No.:153436-54-5
- AG-1478
Catalog No.:BCC3717
CAS No.:153436-53-4
- Gavestinel
Catalog No.:BCC7340
CAS No.:153436-38-5
- Taxcultine
Catalog No.:BCN6948
CAS No.:153415-46-4
- Taxol C
Catalog No.:BCN6941
CAS No.:153415-45-3
- 7-Epi-docetaxel
Catalog No.:BCC5411
CAS No.:153381-68-1
- Ginkgolide K
Catalog No.:BCN8209
CAS No.:153355-70-5
- SCR7
Catalog No.:BCC3978
CAS No.:1533426-72-0
- DFB
Catalog No.:BCC7130
CAS No.:15332-10-2
- Xanthinin
Catalog No.:BCN1686
CAS No.:153483-31-9
- Cevimeline hydrochloride hemihydrate
Catalog No.:BCC1471
CAS No.:153504-70-2
- [D-Trp34]-Neuropeptide Y
Catalog No.:BCC7690
CAS No.:153549-84-9
- Bexarotene
Catalog No.:BCC3737
CAS No.:153559-49-0
- D-Menthol
Catalog No.:BCN4973
CAS No.:15356-60-2
- DL-Menthol
Catalog No.:BCN5950
CAS No.:15356-70-4
- 13-Hydroxylupanine
Catalog No.:BCN3204
CAS No.:15358-48-2
- NS 1619
Catalog No.:BCC7779
CAS No.:153587-01-0
- GNE-9605
Catalog No.:BCC5458
CAS No.:1536200-31-3
- Dofequidar fumarate
Catalog No.:BCC4177
CAS No.:153653-30-6
- H-Ile-OEt.HCl
Catalog No.:BCC2961
CAS No.:15366-32-3
- 9,10-Bis(3,5-dihydroxyphenyl)anthracene
Catalog No.:BCC8793
CAS No.:153715-08-3
Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes.[Pubmed:22031625]
Drug Metab Dispos. 2012 Feb;40(2):267-75.
Substrates of aldehyde oxidase (AO), for which human clinical pharmacokinetics are reported, were selected and evaluated in pooled mixed-gender cryopreserved human hepatocytes in an effort to quantitatively characterize AO activity. Estimated hepatic clearance (Cl(h)) for BIBX1382, carbazeran, O(6)-benzylguanine, zaleplon, and XK-469 using cryopreserved hepatocytes was 18, 17, 12, <4.3, and <4.3 ml . min(-)(1) . kg(-)(1), respectively. The observed metabolic clearance in cryopreserved hepatocytes was confirmed to be a result of AO-mediated metabolism via two approaches. Metabolite identification after incubations in the presence of H(2)(1)(8)O confirmed that the predominant oxidative metabolite was generated by AO, as expected isotope patterns in mass spectra were observed after analysis by high-resolution mass spectrometry. Second, clearance values were efficiently attenuated upon coincubation with hydralazine, an inhibitor of AO. The low exposure after oral doses of BIBX1382 and carbazeran ( approximately 5% F) would have been fairly well predicted using simple hepatic extraction (f(h)) values derived from cryopreserved hepatocytes. In addition, the estimated hepatic clearance value for O(6)-benzylguanine was within approximately 80% of the observed total clearance in humans after intravenous administration (15 ml . min(-)(1) . kg(-)(1)), indicating a reasonable level of quantitative activity from this in vitro system. However, a 3.5-fold underprediction of total clearance was observed for zaleplon, despite the 5-oxo metabolite being clearly observed. These data taken together suggest that the use of cryopreserved hepatocytes may be a practical approach for assessing AO-mediated metabolism in discovery and potentially useful for predicting hepatic clearance of AO substrates.
Chronotropic and inotropic actions of amrinone, carbazeran and isobutylmethyl xanthine: role of phosphodiesterase inhibition.[Pubmed:2478244]
Br J Pharmacol. 1989 Sep;98(1):291-301.
1. The chronotropic and inotropic effects of amrinone, carbazeran and 3-isobutyl-1-methyl xanthine (IBMX) were examined in isolated preparations of papillary muscle and right atria from rabbit heart. The effects of the drugs on cardiac phosphodiesterase and cyclic nucleotide content were also examined. 2. Amrinone (2.4 x 10(-4)M-2 x 10(-3) M), carbazeran (9.1 x 10(-6) M-1.2 x 10(-3) M), and IBMX (1.8 x 10(-5) M-4.5 x 10(-4) M) produced concentration-dependent positive inotropic responses of papillary muscle preparations, the rank order of potency being carbazeran = IBMX greater than amrinone. Sub-threshold positive inotropic concentrations of all three compounds potentiated the positive inotropic effects of isoprenaline; leftward shifts in the concentration-effect curves were 5 fold (IBMX), 11 fold (amrinone) and 46 fold (carbazeran). 3. Amrinone and IBMX produced concentration-dependent positive chronotropic responses in isolated right atria and showed a similar rate selectivity to isoprenaline, but carbazeran elicited a decrease in beating frequency. None of these drugs potentiated the positive chronotropic effects of isoprenaline. 4. Concentrations of amrinone, carbazeran and IBMX that produced similar positive inotropic responses were associated with different increases in papillary muscle cyclic AMP and cyclic GMP concentrations. 5. All three compounds inhibited right atrial and ventricular phosphodiesterase, with amrinone being the least potent. There was, however, a marked difference between the IC50 and EC50 values for phosphodiesterase inhibition and positive inotropy. In contrast the positive chronotropic effects of amrinone and IBMX were observed in the same concentration ranges that produced phosphodiestrease inhibition. 6. The results indicate that amrinone possesses a similar rate/force selectivity to isoprenaline and IBMX. In contrast, carbazeran exerts both positive inotropic and negative chronotropic effects. Phosphodiesterase inhibition and elevation of intracellular cyclic AMP concentration may be involved, at least in part, in the cardiac effects of these drugs.